References
- FireAXuSMontgomeryMKKostasSADriverSEMelloCCPotent and specific genetic interference by double-stranded RNA in Caenorhabditis elegansNature199839166698068119486653
- HannonGJRNA interferenceNature2002418689424425112110901
- MeisterGTuschlTMechanisms of gene silencing by double-stranded RNANature2004431700634334915372041
- NovinaCDSharpPAThe RNAi revolutionNature2004430699616116415241403
- PushparajPNAarthiJJManikandanJKumarSDsiRNA, miRNA, and shRNA: in vivo applicationsJ Dent Res20088711992100318946005
- DavidsonBLMcCrayPBJrCurrent prospects for RNA interference-based therapiesNat Rev Genet201112532934021499294
- Valencia-SanchezMALiuJHannonGJParkerRControl of translation and mRNA degradation by miRNAs and siRNAsGenes Dev200620551552416510870
- BartelDPMicroRNAs: genomics, biogenesis, mechanism, and functionCell2004116228129714744438
- LundESheetsMDImbodenSBDahlbergJELimiting Ago protein restricts RNAi and microRNA biogenesis during early development in Xenopus laevisGenes Dev201125111121113121576259
- ElbashirSMLendeckelWTuschlTRNA interference is mediated by 21- and 22-nucleotide RNAsGenes Dev200115218820011157775
- ZamorePDTuschlTSharpPABartelDPRNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervalsCell20001011253310778853
- LewisBPShihIHJones-RhoadesMWBartelDPBurgeCBPrediction of mammalian microRNA targetsCell2003115778779814697198
- EulalioAHuntzingerEIzaurraldeEGetting to the root of miRNA-mediated gene silencingCell2008132191418191211
- FabianMRSonenbergNFilipowiczWRegulation of mRNA translation and stability by microRNAsAnnu Rev Biochem20107935137920533884
- BhattacharyyaSNHabermacherRMartineUClossEIFilipowiczWRelief of microRNA-mediated translational repression in human cells subjected to stressCell200612561111112416777601
- LiuGWong-StaalFLiQXRecent development of RNAi in drug target discovery and validationDrug Discov Today Technol200633293300
- ElbashirSMHarborthJWeberKTuschlTAnalysis of gene function in somatic mammalian cells using small interfering RNAsMethods200226219921312054897
- LinaWChonggangYDevelopment and applications of RNAi technology in drug researchChin Bull Life Sci200719199213
- ReynoldsALeakeDBoeseQScaringeSMarshallWSKhvorovaARational siRNA design for RNA interferenceNat Biotechnol200422332633014758366
- HarborthJElbashirSMVandenburghKSequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencingAntisense Nucleic Acid Drug Dev20031328310512804036
- ShiraneDSugaoKNamikiSTanabeMIinoMHiroseKEnzymatic production of RNAi libraries from cDNAsNat Genet200436219019614704669
- HeroldMJvan den BrandtJSeiblerJReichardtHMInducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic ratsProc Natl Acad Sci U S A200810547185071851219017805
- LiJHuangLTargeted delivery of RNAi therapeutics for cancer therapyNanomedicine (Lond)20105101483148621143026
- TuschlTExpanding small RNA interferenceNat Biotechnol200220544644811981553
- BrummelkampTRBernardsRAgamiRA system for stable expression of short interfering RNAs in mammalian cellsScience2002296556755055311910072
- TiscorniaGSingerOIkawaMVermaIMA general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNAProc Natl Acad Sci U S A200310041844184812552109
- RubinsonDADillonCPKwiatkowskiAVA lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interferenceNat Genet200333340140612590264
- ChenZStocktonJMathisDBenoistCModeling CTLA4-linked autoimmunity with RNA interference in miceProc Natl Acad Sci U S A200610344164001640517060611
- MatsukuraSJonesPATakaiDEstablishment of conditional vectors for hairpin siRNA knockdownsNucleic Acids Res20033115e7712888529
- ShengYLinCCYueJGeneration and characterization of a Tet-On (rtTA-M2) transgenic ratBMC Dev Biol2010101720158911
- SeiblerJKleinriddersAKüter-LuksBNiehavesSBrüningJCSchwenkFReversible gene knockdown in mice using a tight, inducible shRNA expression systemNucleic Acids Res2007357e5417376804
- AnastassiadisKKimJDaigleNSprengelRSchölerHRStewartAFA predictable ligand regulated expression strategy for stably integrated transgenes in mammalian cells in cultureGene2002298215917212426104
- SzymczakALVignaliDADevelopment of 2A peptide-based strategies in the design of multicistronic vectorsExpert Opin Biol Ther20055562763815934839
- AbdelmawlaSGuoSZhangLPharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic deliveryMol Ther20111971312132221468004
- WoodleMCLuPYNanoparticles deliver RNAi therapyMater Today200588 Suppl 13441
- AllenTMCullisPRDrug delivery systems: entering the mainstreamScience200430356651818182215031496
- van den BoornJGSchleeMCochCHartmannGSiRNA delivery with exosome nanoparticlesNat Biotechnol201129432532621478846
- LaresMRRossiJJOuelletDLRNAi and small interfering RNAs in human disease therapeutic applicationsTrends Biotechnol2010281157057920833440
- SuttonDKimSShuaiXEfficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitroInt J Nanomedicine20061215516217722531
- WuYWangWChenYThe investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitroInt J Nanomedicine2010512913620309399
- YamamichiKUeharaYKitamuraNNakaneYHiokiKIncreased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancerInt J Cancer19987932562629645347
- KurozumiKNishidaTNakaoKNakaharaMTsujimotoMExpression of CD44 variant 6 and lymphatic invasion: importance to lymph node metastasis in gastric cancerWorld J Surg19982288538579673558
- MiyoshiHBlomerUTakahashiMGageFHVermaIMDevelopment of a self-inactivating lentivirus vectorJ Virol19987210815081579733856
- VandenDriesscheTThorrezLNaldiniLLentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivoBlood2002100381382212130491
- Hacein-Bey-AbinaSVon KalleCSchmidtMLMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1Science2003302564441541914564000
- HannonGJRossiJJUnlocking the potential of the human genome with RNA interferenceNature2004431700637137815372045
- RaoulCAbbas-TerkiTBensadounJCLentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALSNat Med2005114342342815768028
- McKinleyMPBoltonDCPrusinerSBA protease-resistant protein is a structural component of the Scrapie prionCell198335157626414721
- BoltonDMcKinleyMPrusinerSIdentification of a protein that purifies with the scrapie prionScience19822184579130913116815801
- GieseABrownDRGroschupMHFeldmannCHaistIKretzschmarHARole of microglia in neuronal cell death in prion diseaseBrain Pathol1998834494579669696
- BuelerHRaeberASailerAFischerMAguzziAWeissmannCHigh prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP geneMol Med19941119308790598
- PfeiferAEigenbrodSAl-KhadraSLentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected miceJ Clin Invest2006116123204321017143329
- MallucciGDickinsonALinehanJKlöhnPCBrandnerSCollingeJDepleting neuronal PrP in prion infection prevents disease and reverses spongiosisScience2003302564687187414593181
- GallozziMChapuisJLe ProvostFPrnp knockdown in transgenic mice using RNA interferenceTransgenic Res200817578379118350371
- PulfordBReimNBellALiposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell culturesPLoS One201056e1108520559428
- BergerEAMurphyPMFarberJMChemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and diseaseAnn Rev Immunol199917165770010358771
- MooreJPTrkolaADragicTCo-receptors for HIV-1 entryCurr Opin Immunol1997945515629287172
- MosierDVirus and target cell evolution in human immunodeficiency virus type 1 infectionImmunol Res200021225325810852125
- SimmonsGReevesJDHibbittsSCo-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligandsImmunol Rev2000177111212611138769
- O’BrienSJNelsonGWHuman genes that limit AIDSNat Genet200436656557415167933
- SmithMWDeanMCarringtonMContrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE StudyScience199727753289599659252328
- ShimizuSHongPArumugamBA highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse modelBlood201011581534154420018916
- ZhangSZhaoBJiangHWangBMaBCationic lipids and polymers mediated vectors for delivery of siRNAJ Control Release2007123111017716771
- AndersenMOHowardKAPaludanSRBesenbacherFKjemsJDelivery of siRNA from lyophilized polymeric surfacesBiomaterials200829450651217950838
- KumarPWuHMcBrideJLTransvascular delivery of small interfering RNA to the central nervous systemNature20074487149394317572664
- LafonMRabies virus receptorsJ Neurovirol2005111828715804965
- MorrisseyDVLockridgeJAShawLPotent and persistent in vivo anti-HBV activity of chemically modified siRNAsNat Biotechnol20052381002100716041363
- RichardsDIvanisevicAInorganic material coatings and their effect on cytotoxicityChem Soc Rev20124162052206022116515
- RippelRASeifalianAMGold revolution – gold nanoparticles for modern medicine and surgeryJ Nanosci Nanotechnol20111153740374821780364
- GhoshPHanGDeMKimCKRotelloVMGold nanoparticles in delivery applicationsAdv Drug Deliv Rev200860111307131518555555
- GuoSHuangYJiangQEnhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyteACS Nano2010495505551120707386
- ChenAMTaratulaOWeiDLabile catalytic packaging of DNA/siRNA: control of gold nanoparticles “out” of DNA/siRNA complexesACS Nano2010473679368820521827
- ThomasMKlibanovAMConjugation to gold nanoparticles enhances polyethylenimine’s transfer of plasmid DNA into mammalian cellsProc Natl Acad Sci U S A2003100169138914312886020
- RosiNLGiljohannDAThaxtonCSLytton-JeanAKRHanMSMirkinCAOligonucleotide-modified gold nanoparticles for intracellular gene regulationScience200631257761027103016709779
- ElbakryAZakyALieblRRachelRGoepferichABreunigMLayer-by-layer assembled gold nanoparticles for siRNA deliveryNano Lett2009952059206419331425
- LeeJSGreenJJLoveKTSunshineJLangerRAndersonDGGold, poly(beta-amino ester) nanoparticles for small interfering RNA deliveryNano Lett2009962402240619422265
- SongWJDuJZSunTMZhangPZWangJGold nanoparticles capped with polyethyleneimine for enhanced siRNA deliverySmall20106223924619924738
- ZuckermanJEChoiCHJHanHDavisMEPolycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membraneProc Natl Acad Sci U S A201210983137314222315430
- KongWBaeKJoSKimJParkTCationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehiclesPharm Res201229236237421842305
- SokolovKFollenMAaronJReal-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticlesCancer Res20036391999200412727808
- XiDLuoXNingQLuQYaoKLiuZThe detection of HBV DNA with gold nanoparticle gene probesJournal of Nanjing Medical University2007214207212
- BaptistaPVKoziol-MontewkaMPaluch-OlesJDoriaGFrancoRGold nanoparticle probe-based assay for rapid and direct detection of Mycobacterium tuberculosis DNA in clinical samplesClin Chem20065271433143416798971
- GeorganopoulouDGChangLNamJMNanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s diseaseProc Natl Acad Sci U S A200510272273227615695586
- MahmoudKALuongJHTImpedance method for detecting HIV-1 protease and screening for its inhibitors using ferrocene-peptide conjugate/Au nanoparticle/single-walled carbon nanotube modified electrodeAnal Chem200880187056706218707132
- GuoPEricksonSAndersonDA small viral RNA is required for in vitro packaging of bacteriophage phi 29 DNAScience198723648026906943107124
- HoeprichSGuoPComputer modeling of three-dimensional structure of DNA-packaging RNA (pRNA) monomer, dimer, and hexamer of Phi29 DNA packaging motorJ Biol Chem200227723207942080311886855
- KhaledAGuoSLiFGuoPControllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnologyNano Lett2005591797180816159227
- ChenCShengSShaoZGuoPA dimer as a building block in assembling RNAJ Biol Chem200027523175101751610748150
- ZhangCLeeCSGuoPThe proximate 5′ and 3′ ends of the 120-base viral RNA (pRNA) are crucial for the packaging of bacteriophage Ø29 DNAVirology1994201177858178491
- GarverKGuoPBoundary of pRNA functional domains and minimum pRNA sequence requirement for specific connector binding and DNA packaging of phage phi29RNA199739106810799292504
- ReidRJBodleyJWAndersonDCharacterization of the prohead-pRNA interaction of bacteriophage phi 29J Biol Chem19942697515751628106496
- ChenCZhangCGuoPSequence requirement for hand-in-hand interaction in formation of RNA dimers and hexamers to gear phi29 DNA translocation motorRNA19995680581810376879
- ZhangCTrottierMGuoPCircularly permuted viral pRNA active and specific in the packaging of bacteriophage φ 29 DNAVirology199520724424517533964
- GuoSTschammerNMohammedSGuoPSpecific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNAHum Gene Ther20051691097110916149908
- GuoSHuangFGuoPConstruction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cellsGene Ther2006131081482016482206
- LiuJGuoSCinierMFabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packagingACS Nano20105123724621155596
- DavisMEZuckermanJEChoiCHJEvidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature201046472911067107020305636
- KimSSPeerDKumarPRNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT miceMol Ther201018237037619997090
- XinpingLApplications of RNA interference technology to drug studyChinese Pharmacological Bulletin2005214400403
- TheFreeLibrary.com [homepage on the Internet]OPKO Health Announces Update on Phase III Clinical Trial of BevasiranibPennsylvaniaFarlex, Inc.2012 [updated 2009 May 6; cited 2012 Apr 10]. Available from: http://www.thefreelibrary.com/OPKO+Health+Announces+Update+on+Phase+III+Clinical+Trial+of...-a0195014938. Accessed Jun 25, 2012.
- Quarkpharma.com [homepage on the Internet]Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3CaliforniaQuark Pharmaceuticals, Inc.2007 [updated 2009 May 11; cited 2012 Apr 10]. Available from: http://www.quarkpharma.com/qbi-en/newslist/arvo/. Accessed Jun 25, 2012.
- Tekmirapharm.com [homepage on the Internet]Tekmira Provides Corporate Update and Announces First Quarter 2012 ResultsBritish ColumbiaTekmira Pharmaceuticals Corp.2012 [updated 2012 May 15; cited 2012 Apr 10]. Available from: http://investor.tekmirapharm.com/releasedetail.cfm?releaseid=673804. Accessed Jun 22, 2012
- Tekmirapharm.com [homepage on the Internet]Tekmira Announces Initiation of TKM-Ebola Phase 1 Clinical TrialBritish ColumbiaTekmira Pharmaceuticals Corp.2012 [updated 2012 Feb 8; cited 2012 Apr 10]. Available from: http://files.shareholder.com/downloads/ABEA-50QJTB/1754071349x0x541056/d731bed8-39f3-4fe2-a962-c86e2f72e681/TKMR_News_2012_2_8_General_Releases.pdf.Accessed Jun 24, 2012
- Pharmaceuticals A Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) In: Clinical-Trialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012 [updated 2012 May 30]. Available from: http://clinicaltrials.gov/ct2/show/NCT01065935?term=Alnylam&rank=5. ClinicalTrials.gov Identifier: NCT01065935. Accessed Jul 11, 2012
- Quarkpharma.com [homepage on the Internet]. Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 California: Quark Pharmaceuticals, Inc.; c 2007 [updated 2012 Jan 4; cited 2012 Apr 10]. Available from: http://www.quarkpharma.com/qbi-en/newslist/clinicalstudyqpi-1007/. Accessed Jun 21, 2012.
- Pharmaceuticals A. Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement In: ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2011 [updated 2011 Aug 23]. Available from: http://clinicaltrials.gov/ct2/show/NCT00882180?term=Alnylam&rank=3. ClinicalTrials.gov Identifier: NCT00882180. Accessed Jul 11, 2012
- Calando.com [homepage on the Internet]Arrowhead Research Subsidiary, Calando Pharmaceuticals, Provides First Proof of RNA Interference in Humans with Systemically Administered siRNA Therapeutic Clinical Trial Results Published inNature CaliforniaCalando Pharmaceuticals2012 [updated 2010 Mar 22; cited 2012 Apr 11]. Available from: http://www.calandopharma.com/newspdfs/NR--Calando_data--3-22-10_final.pdf. Accessed Jun 19, 2012
- Project PC. Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita In: ClinicalTrials gov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2008 [updated 2008 Nov 18]. Available from: http://clinicaltrials.gov/ct2/show/NCT00716014. ClinicalTrials.gov Identifier: NCT00716014. Accessed Jul 11, 2012.
- Genomeweb.com [homepage on the Internet]Allergan Drops Development of siRNA Rx for AMD on Poor Phase II DataNew YorkGenomeWeb LLC.2012 [updated 2009 May 28; cited 2012 Apr 11]. Available from: http://www.genomeweb.com/rnai/allergan-drops-development-sirna-rx-amd-poor-phase-ii-data. Accessed June 21, 2012
- Quarkpharma.com [homepage on the Internet]. QPI-1002. California: Quark Pharmaceuticals, Inc.; c 2007 [updated 2010 Aug 18; cited 2012 Apr 10]. Available from: http://www.quarkpharma.com/qbi-en/products/QPI-1002da/. Accessed Jun 15, 2012
- TheFreeLibrary.com [homepage on the Internet]. Santaris Pharma A/S Advances a Second Drug From Its Cardiometabolic Program, SPC4955, Inhibiting apoB, into Phase 1 Clinical Trials for the Treatment of High Cholesterol. Pennsylvania: Farlex, Inc.; c 2012 [updated 2011 May 11; cited 2012 Apr 10]. Available from: http://www.thefreeli-brary.com/Santaris+Pharma+A%2fS+Advances+a+Second+Drug+From+Its+Cardiometabolic...-a0256048995. Accessed May 11, 2012
- Pharmaceuticals A. Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C) In: ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012 [updated 2012 Apr 20]. Available from: http://clinicaltrials.gov/ct2/show/NCT01437059?term=PCS02&rank=1. ClinicalTrials.gov Identifier: NCT01437059. Accessed Jul 11, 2012
- Santaris.com [homepage on the Internet]. Santaris Pharma A/S advances new cholesterol-lowering drug, SPC5001 inhibiting exciting new target PCSK9, into Phase 1 clinical trials for the treatment of high cholesterol. San Diego: Santaris Pharma A/S; c 2011 [updated 2011 May 4; cited 2012 Apr 9]. Available from: http://www.santaris.com/news/2011/05/04/santaris-pharma-advances-new-cholesterol-lowering-drug-spc5001-inhibiting-exciting-n. Accessed Jun 25, 2012
- Tekmirapharm.com [homepage on the Internet]. Tekmira Pharmaceuticals Completes ApoB SNALP Phase 1 Clinical Trial. British Columbia: Tekmira Pharmaceuticals Corp.; c 2012 [updated 2010 Jan 7; cited 2012 Apr 10]. Available from: http://files.shareholder.com/downloads/ABEA-50QJTB/1754071349x0x425312/9b404e8f-82e2-48a8-ba61-7132-8539afd9/TKM_News_2010_1_7_General_Releases.pdf. Accessed Jun 29, 2012
- Giiresearch.com [homepage on the Internet]. Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The challenge of turning technology into therapy. Kawasaki: Global Information, Inc.; c 1997–2007 [updated 2011 Aug 12; cited 2012 Apr 11]. Available from: http://www.giiresearch.com/report/kt55538-therapy-prod.html. Accessed Jun 26, 2012
- Abnnewswire.net [homepage on the Internet]. rHIV7-shI-TAR-CCR5RZ. New York: ABN Newswire; c 2012 [updated 2010 Nov 1; cited 2012 Apr 11]. Available from: http://www.abnnewswire.net/search.asp?cp=utf-8&lang=_c&site=press_c&client=press-search-cs&output=xml_no_dtd&proxystylesheet=press-search-cs&proxyreload=1&filter=p&getfields=*&way=abn&way=web&qu=rHIV7-shI-TAR-CCR5RZ&stype=press_c&image2.x=33&image2.y=10. Accessed Jun 18, 2012.
- Pharmaceuticals A. Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis In: ClinicalTrials gov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012 [updated 2012 May 23]. Available from: http://clinicaltrials.gov/ct2/show/NCT01148953?term=Alnylam&rank=4. ClinicalTrials.gov Identifier: NCT01148953. Accessed Jul 11, 2012.